- $145.19m
- $51.66m
- $138.90m
Quanterix Corp reports results for the quarter ended in March - Earnings Summary
Brief: Quanterix Q1 product revenue USD 19.287 million
Brief: Quanterix Releases Operating Results For First Quarter 2023
Quanterix Corp expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Accelerates Approval Of Tofersen
Brief: Quanterix - Entered Into Amended & Restated Employment Agreement With CFO Michael Doyle, Related To Planned Transition To Retirement In 2024
U.S. STOCKS ON THE MOVE-Meta Platforms, BlackBerry, Rivian Automotive, Cara Therapeutics
U.S. RESEARCH ROUNDUP-Esperion Therapeutics, Office Properties Income Trust, Radius Global Infrastructure
Quanterix rises as Q4 results beat expectations
Quanterix Corp reports results for the quarter ended in December - Earnings Summary
Brief: Quanterix Q4 Basic Shr Loss USD 0.5
Brief: Quanterix Releases Operating Results For Fourth Quarter and Full Year 2022 Aligned With Expectations
Quanterix Corp expected to post a loss of 47 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 47 cents a share - Earnings Preview
Brief: Quanterix To Participate In The 15th Clinical Trials On Alzheimer's Disease Task Force
Quanterix Corp reports results for the quarter ended in September - Earnings Summary
Brief: Quanterix Corp's Q3 Revenue Rose 13% To $26.6 Million
Quanterix Corp expected to post a loss of 42 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 42 cents a share - Earnings Preview